GSK
GSK
722 hedge funds and large institutions have $15.2B invested in GSK in 2014 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 325 increasing their positions, 215 reducing their positions, and 36 closing their positions.
51% more repeat investments, than reductions
Existing positions increased: 325 | Existing positions reduced: 215
42% more call options, than puts
Call options by funds: $117M | Put options by funds: $82.4M
31% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 36
6% more capital invested
Capital invested by funds: $14.4B → $15.2B (+$803M)
1% more funds holding
Funds holding: 712 → 722 (+10)
0.25% more ownership
Funds ownership: 4.43% → 4.67% (+0.25%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
+$392M |
| 2 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$266M |
| 3 |
MAA
Managed Account Advisors
Jersey City,
New Jersey
|
+$112M |
| 4 |
Renaissance Technologies
New York
|
+$101M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$84.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$218M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$149M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$72.1M |
| 4 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
-$64.2M |
| 5 |
PP
PDT Partners
New York
|
-$19.5M |
GSK Hedge Fund Activity: Q2 2014 in Review
722 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2014, worth a combined $15.2B — up 5.6% from $14.4B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new GSK positions and 36 closed out — a net gain of 11 holders — while 325 added to existing stakes and 215 trimmed.
The largest buyer was Allianz Asset Management, opening a new position worth an estimated $392M. The largest seller was Primecap Management, cutting an estimated $218M.
- 722 institutional investors held GSK (GSK) as of Q2 2014, up from 712 in Q1 2014.
- Funds reported $15.2B of GSK stock for Q2 2014, up 5.6% quarter-over-quarter.
- 47 funds opened new GSK positions in Q2 2014 and 36 closed out, a net change of +11 holders.
- The largest GSK buyer in Q2 2014 was Allianz Asset Management, an estimated $392M added.
- The largest GSK seller in Q2 2014 was Primecap Management, an estimated $218M sold.
Based on aggregated 13F filings for Q2 2014.